Struggling to find Capivasertib (Truqap)? Learn why this breast cancer drug is hard to get, what causes delays, and what you can do in 2026.
If you or a loved one has been prescribed Capivasertib (brand name Truqap) for breast cancer, you may have already discovered that filling this prescription is not as simple as walking into your local pharmacy. You're not alone — many patients across the country are running into roadblocks when trying to get this medication.
In this guide, we'll explain what Capivasertib is, why it can be so difficult to find, and what steps you can take to get your medication faster.
Capivasertib, sold under the brand name Truqap, is a first-in-class AKT inhibitor made by AstraZeneca. It was approved by the FDA in November 2023 for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer with certain gene mutations (PIK3CA, AKT1, or PTEN alterations).
It works by blocking the AKT protein, which plays a key role in how cancer cells grow and divide. Truqap is taken as an oral tablet — 400 mg twice daily for 4 days on, 3 days off — in combination with Fulvestrant (Faslodex) injections. For more details on the drug itself, check out our guide on what Capivasertib is and how it's used.
There are several reasons patients struggle to access Capivasertib in 2026. Here are the most common ones:
Truqap is not stocked at your typical retail pharmacy like CVS or Walgreens. As a specialty oncology medication, it is distributed through limited specialty pharmacy networks. This means your local pharmacist likely cannot order it, and you'll need to go through a designated specialty pharmacy — which adds extra steps and processing time.
Most insurance plans — including commercial insurance and Medicare Part D — require prior authorization before they will cover Capivasertib. This means your oncologist must submit documentation proving that:
This process can take days or even weeks, during which you're waiting without your medication.
Before you can even be prescribed Capivasertib, your cancer must be tested with a specific genetic test. The FoundationOne CDx companion diagnostic is required to confirm that your tumor has the right gene alterations. Getting this test ordered, processed, and returned can add additional weeks to the timeline.
The cash price of Truqap is approximately $23,762 per 28-day cycle. Even with insurance, copays for specialty cancer drugs can be significant. Some patients face delays while navigating financial assistance programs or appealing insurance denials. To learn about ways to reduce costs, see our article on how to save money on Capivasertib.
While the process can feel overwhelming, there are concrete steps you can take:
Your cancer care team's office staff often has experience navigating prior authorizations for specialty drugs. Ask them to start the process immediately after your genetic test results come back. Some offices have dedicated staff or work with AstraZeneca's Access 360 support program to speed things along.
Tools like Medfinder can help you identify which specialty pharmacies have Capivasertib in stock, reducing the guesswork. For step-by-step tips, read our guide on how to find Capivasertib in stock near you.
Don't wait until you get a bill. Contact AstraZeneca Access 360 at 844-275-2360 or visit MyAccess360.com as soon as Capivasertib is prescribed. The Truqap Co-Pay Savings Program can bring your monthly cost to as low as $0 for commercially insured patients.
If you're uninsured or underinsured, the AZ&Me Prescription Savings Program may provide Truqap at no cost. Your oncologist's office can help you apply.
If one specialty pharmacy is experiencing delays, ask your doctor if your prescription can be transferred to another in-network specialty pharmacy. Sometimes a different pharmacy can fill it faster. Learn more in our article about how to check if a pharmacy has Capivasertib in stock.
Finding Capivasertib can be frustrating, especially when you're dealing with a cancer diagnosis. The good news is that the medication itself is not in a traditional shortage — the challenges are mostly about insurance approvals, specialty pharmacy logistics, and cost. By being proactive and using the resources available to you, you can reduce delays and get your treatment started sooner.
If you're still having trouble, Medfinder is here to help you navigate the process and find Capivasertib in stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
